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Background: Mild hypoxia is common in stroke patients and may have significant adverse effects on the ischemic
brain after stroke. The use of oxygen treatment is rapidly increasing in European stroke units but is not without side
effects. It impedes early mobilization, could pose an infection risk, and may encourage the formation of toxic free
radicals, leading to further damage to the ischemic brain. In the Stroke Oxygen Pilot Study (2 or 3 L/min for
72 hours) neurological recovery at one week was better in the oxygen group than in controls, and after correction
for difference in baseline stroke severity and prognostic factors, there was a trend to better outcome with oxygen
at six months. Oxygen was as effective in mild as in severe strokes.
Oxygen saturation is lower at night than during the day, and episodes of oxygen desaturation are common during
sleep. Nocturnal oxygen supplementation is likely to reduce the burden of hypoxia without interfering with
daytime mobilization and rehabilitation.
Before wider use of oxygen supplementation becomes established it is important to obtain better evidence on
which patients benefit from such treatment.
Methods: Participants will be randomized to one of three groups: the first will receive continuous oxygen for
72 hours (at a rate of 2 or 3 L/min depending on baseline oxygen saturation), the second group will receive
nocturnal oxygen only (at a rate of 2 or 3 L/min depending on baseline oxygen saturation) and the third group will
not receive any oxygen (control). A baseline assessment is performed at randomization and a one-week follow-up
completed. Outcome data at three, six and twelve months will be obtained via a questionnaire sent to the patient
by the trial center.
Discussion: This study will provide evidence on the effectiveness of oxygen supplementation for the treatment of
stroke and whether nocturnal oxygen is a potentially beneficial therapy regimen.
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Why is there a need to investigate the effects of oxygen
supplementation after stroke?
It is now well established that specialist care on stroke
units is effective in preventing death and disability after
stroke [1]. It remains unclear, however, which aspects of
stroke care are crucial for improving outcome. It has been
shown that patients on a stroke unit are more likely to re-
ceive oxygen than those on a non-specialized general ward
[2]. Mild hypoxia is common in stroke patients and may
have significant adverse effects on the ischemic brain after
stroke [3]. Hypoxemia in the first few hours after hospital
admission is associated with an increased risk of death [4].
While healthy adults with normal cerebral circulation can
compensate for mild hypoxia with an increase in cerebral
blood flow [5], this is not possible in the already ischemic
brain after stroke [6-8]. The use of oxygen treatment is
rapidly increasing in European stroke units. A question-
naire survey of UK stroke physicians showed that almost
50% of respondents would start oxygen supplementation
after stroke at an oxygen saturation level of 95% or above
[9], which is well within the normal physiological range
[10]. In many UK Accident and Emergency departments,
oxygen is given routinely to stroke patients irrespective of
blood oxygen levels.
Oxygen treatment is not without side effects [11]. It im-
pedes early mobilization and could pose an infection risk.
There is evidence from animal models and in vitro studies
that oxygen encourages the formation of toxic free radi-
cals, leading to further damage to the ischemic brain
[12-15], especially during reperfusion. Marked changes in
adenosine triphosphate (ATP) and related energy metabo-
lites develop quickly in response to acute ischemia and
tissue hypoxia. These alterations are only partially re-
versed on reperfusion, despite improved oxygen delivery.
Ischemia-induced decrease in the mitochondrial capacity
for respiration results in reduced oxygen consumption
and increased free radical generation during reperfusion
[16]. Oxidative stress has also been implicated in the acti-
vation of cell-signaling pathways that lead to apoptosis
and neuronal cell death [17,18]. While much research
points towards adverse effects of hyperoxia in the ischae-
mic brain, there is also evidence to support the notion that
therapy-induced eubaric hyperoxia may be neuroprotec-
tive [19,20]. Routine oxygen supplementation for acute
myocardial infarction has been abandoned after a clinical
trial showed no benefit, and potential harm [21]. A quasi-
randomized study of oxygen supplementation for acute
stroke by Ronning and Guldvog [22] has shown that rou-
tine oxygen treatment in unselected stroke patients does
not reduce morbidity and mortality. Subgroup analyses
within their study suggested that patients with severe
strokes were more likely to benefit than those with mild
strokes; however the study size was too small to definewith certainty patients who are likely to derive benefit. A
recent very small study [23] of high-flow oxygen treatment
after acute stroke showed that cerebral blood volume and
blood flow within ischemic regions improved with hyper-
oxia. Within 24 hours magnetic resonance imaging of the
brain showed reperfusion in 50% of hyperoxia-treated pa-
tients versus 17% of controls (p = 0.06) but no long-term
clinical benefit at three months [23]. In the recently
completed Stroke Oxygen Pilot Study, the flow rate of
oxygen was lower (2 or 3 L/min dependent on baseline
oxygen saturation) and treatment was continued for lon-
ger (72 hours) [24,25]. Neurological recovery at one week
was better in the oxygen group than in the controls. While
there was no difference in outcome at six months on dir-
ect comparison, there was a trend for a better outcome
with oxygen after correction for differences in baseline
stroke severity and prognostic factors. Oxygen was as ef-
fective in mild as in severe strokes, in contrast to the earl-
ier study by Ronning and Guldvog [22]. These results are
promising, but need confirmation in a larger study.
Clinical guidelines on oxygen supplementation after
stroke are not based on evidence from randomized clinical
trials [26], differ from country to country, and change over
time without obvious reason. The European Stroke Initia-
tive (2008) suggests that routine oxygen supplementation
to all stroke patients has not been shown to be effective,
but that adequate oxygenation is important and that
oxygenation can be improved by giving oxygen at a rate
of >2 L/min (no target saturation or supporting evidence
given) [27]. In 2003, the American Stroke Association
Guideline recommended keeping the oxygen saturation
level at or above 95% [28]. There was no change to the
recommendations in the 2005 update of the guideline
[29], but in 2007 the advice was revised to say that oxygen
saturation should be maintained at or above 92% [30].
The latest UK National Clinical Guideline for the manage-
ment of people with stroke (July 2008) [31] and the 2008
guidance from the National Institute for Clinical Excel-
lence [32] state that supplemental oxygen should only be
given to people who have had a stroke if the oxygen satur-
ation falls below 95%. None of the recommendations are
based on evidence from controlled clinical trials. Not sur-
prisingly, there is uncertainty amongst physicians treating
patients with stroke about which treatment approach to
take and when to give oxygen, as shown by a recent sur-
vey of British Stroke Physicians [9].
For all the above reasons it is important to identify the
groups of patients who benefit from oxygen, and the
others who do not.
What is the justification for the fixed dose oxygen regime
suggested for this study?
A fixed dosage scheme has been chosen to keep the de-
sign of the study as simple as possible so that any
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be carried out in day-to-day clinical practice.
Ronning and Guldvog have shown that giving oxygen at
a rate of 3 L/min to all stroke patients during the first
24 hours after hospital admission does not improve overall
outcome [22]. They did not report baseline oxygen satur-
ation or changes in saturation on treatment. It is therefore
possible that some patients were undertreated and others
achieved excessively high oxygen levels, leading to an in-
crease in free radical generation in the ischemic penumbra
[33]. There are no other data from clinical studies to in-
form recommendations for the dose of oxygen to give.
The recently updated European Stroke Initiative suggests
a dose of 2 to 4 L/min [34], and the American Stroke As-
sociation Guideline recommends keeping the oxygen sat-
uration at or above 95% [28-30], but neither of these
recommendations is based on evidence from controlled
clinical trials. In the absence of data to the contrary it is
reasonable to assume that treatment should restore oxy-
gen saturation to the normal range.
Normal oxygen saturation for adults is 95.0 to 98.5%
[35]; in healthy older individuals it is lower at 95% ±
2.5% [10]. Oxygen saturation in stroke patients who are
normoxic at recruitment is about 1% lower than that of
age-matched community controls [36]. A recently com-
pleted dose titration study for oxygen after acute stroke
found that 2 L/min oxygen by nasal cannulae increases
oxygen saturation by 2% and 3 L/min by 3% [37]. It was
also found that oxygen masks were less likely to be toler-
ated than nasal cannulae, leading to poorer treatment
compliance with the former. For this study it was there-
fore decided to give oxygen by nasal cannulae. A dosage
regimen of 3 L/min for individuals with a baseline oxy-
gen saturation of ≤93% and 2 L/min for individuals with
a baseline saturation >93% is likely to prevent hypoxia
without increasing oxygen saturation beyond the upper
limit of the normal range.
What are the advantages of giving routine oxygen
supplementation at night only?
Patients are more likely to be hypoxic at night
The mean nocturnal oxygen saturation is about 1%
lower than mean oxygen saturation when awake, in both
stroke patients and controls [38]. A recent study in our
unit has shown that a quarter of patients who are nor-
moxic in the day have significant hypoxia during the
night. About 60 to 70% of stroke patients suffer from
sleep apnea early after the stroke [38-40].
The development of hypoxia is more likely to be missed
at night
It is more difficult to observe patients in a darkened
room and, unless there are reasons to suspect the pa-
tient is unwell, nurses will not wake the patient forroutine observations. The development of hypoxia is
therefore more likely to be missed at night.
Nocturnal hypoxemia is more likely to lead to brain tissue
hypoxia at night
A recent study in normal volunteers has shown that
hypoxemia leads to a compensatory increase in cerebral
blood flow during wakefulness, but not during sleep, and
is therefore more likely to result in brain tissue hypoxia
at night [41].
Nocturnal oxygen supplementation does not interfere with
the patient’s daytime mobility
Early mobilization is an important factor determining
good outcome [2]. Patients who are attached to monitor-
ing or oxygen supplementation equipment are less likely
to be mobilized than patients who are not.
Giving routine oxygen only at night might prevent a
significant number of otherwise undetected episodes of
hypoxia, without interfering with the patient’s daytime
rehabilitation.
Methods/Design
Study design
The design of the study is as follows: a multi-center, pro-
spective, randomized, open, blinded-endpoint study of
routine oxygen supplementation after acute stroke ver-
sus no routine oxygen treatment (Figure 1).
Trial hypothesis
The primary hypothesis is that fixed dose oxygen treat-
ment during the first three days after an acute stroke im-
proves outcome after stroke.
The secondary hypothesis is that restricting oxygen
supplementation to night time only is more effective
than continuous supplementation.
Recruitment
Patients will be recruited from multiple (>30) centers
throughout the UK and worldwide. The first study cen-
ter to be enrolled will be the University Hospital of
North Staffordshire. Centers will be eligible for partici-
pation in the study if they admit patients with acute
stroke, are able to provide oxygen treatment and moni-
tor oxygen saturation, and if there is a local researcher
who will act as the principal investigator for the locality.
Inclusion criteria
All adult patients with an acute stroke will be eligible to
be considered for study participation. There are no defin-
ite guidelines for oxygen treatment after acute stroke, and
there is uncertainty among stroke physicians about who
should be given oxygen and for how long. The eligibility
criteria for inclusion in the trial reflect this uncertainty,
Figure 1 The Stroke Oxygen Supplementation Study (SO2S) flowchart. The SO2S randomizes stroke patients to one of three treatment
groups, nocturnal oxygen for three nights, continuous oxygen for 72 hours or no oxygen. Patients are then followed-up at one-week, three, six
and twelve months post randomization.
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who do not have definite indications for or definite con-
traindications to oxygen treatment.
Hence, adult patients will be eligible for trial inclusion
if they were admitted with symptoms of an acute stroke
within the preceding 24 hours, and in the doctor’s opin-
ion there is no clear indication for, and no clear contra-
indication to oxygen treatment.
The diagnosis of stroke will be made by history and clin-
ical examination and is at the discretion of the admitting
doctor. It will based on the World Health Organization
(WHO) criteria (rapidly developing clinical signs of focal or
global disturbance of cerebral function, with symptoms last-
ing 24 hours or longer, or leading to death, with no apparent
cause other than of vascular origin) [42]. Within the first
24 hours of symptom onset a definite distinction between a
stroke and a transient ischemic attack cannot be made.
However, most patients who still have persistent symptoms
after one hour will be confirmed to be having a stroke. Since
waiting for 24 hours for confirmation would unnecessarily
delay treatment, we omitted the time element from the def-
inition of stroke for the purposes of trial inclusion.
Exclusion criteria
Patients will be excluded from the trial if the responsible
doctor considers the patient to have definite indicationsfor, or contraindications to, oxygen treatment at a rate
of 2 to 3 L/min. The decision will be left to the respon-
sible clinician. This exclusion criterion has been chosen
to ensure that all patients are treated according to best
medical practice.
Potential indications for oxygen treatment could be:
oxygen saturation on air <90%, hypoxia associated with
acute left ventricular failure, severe pneumonia, pulmon-
ary embolus, and chronic respiratory failure treated with
long term oxygen at home.
Potential contraindications to fixed dose oxygen treat-
ment could be type two respiratory failure and very se-
vere hypoxia.
Patients will also be excluded if the stroke is not the
main clinical problem, or if they have another serious
life-threatening illness likely to lead to death within the
subsequent few months. This group of patients is ex-
cluded because it is unlikely that they are going to derive
any benefit from the trial treatment.
Intervention
Patients will be randomized to one of three treatment groups:
Treatment group 1: no routine oxygen supplementa-
tion during the first 72 hours after randomization.
Treatment group 2: oxygen per nasal cannulae over-
night (9 pm to 7 am) at a flow rate of 3 L/min (if baseline
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2 L/min (if baseline oxygen saturation is greater than
93%) during the first three nights after randomization.
Treatment group 3: oxygen per nasal cannulae con-
tinuously (day and night) at a flow rate of 3 L/min (if
baseline oxygen saturation is 93% or below) or a flow
rate of 2 L/min (if baseline oxygen saturation is greater
than 93%) during the first 72 hours after randomization.
All patients will have regular observations of vital signs
(blood pressure, heart rate, temperature and oxygen sat-
uration) every six hours or less, as per the local protocol
of the stroke unit. Treatment of any abnormal findings
will be independent of trial allocation. Patients who re-
quire oxygen, or changes in the dose of oxygen, for clin-
ical reasons at any time of the trial will be given the
concentration of oxygen they require.
Blinding
This study will be open, since placebo treatment (room
air) would have similar side effects as the active treatment
(such as infection and immobilization), and would thus
bias the data in favor of the treatment group. The main
outcomes will be ascertained at three months by central
follow-up, ensuring that the assessor is blind to the inter-
vention. When the patients complete the questionnaire
they may have some recollection of being treated with
oxygen or not. Patients will be asked to state on the ques-
tionnaire if they remember or can guess which treatment
group they were in. This will then be compared with the
actual allocation to quantify potential bias.
Initial assessment
The initial assessment will be done by the researcher
randomizing the patient, or entered online for patients
randomized via the web, or sent to the trial center by
fax for patients randomized via the telephone. It will in-
clude: baseline demographics, date and time of event,
the Glasgow Coma Scale [43], predictors of outcome
[44] and the National Institutes of Health Stroke Scale
(NIHSS) [45,46].
Follow-up assessments
Week one
The one-week assessment will confirm the diagnosis, and
will document deaths and neurological status (NIHSS),
compliance with the intervention, and complications. It
will be performed by a member of the local research team
trained in the assessment tools seven days (± one day to
allow for weekends and holidays) after enrolment. In the
case of patients who are discharged before the end of one
week, or who cannot be followed at seven days, the patient
will be assessed at discharge and if appropriate the follow-
up completed at this time point. Wherever possible
we will strive to assess the patient at day seven afterrandomization in hospital or, if discharged, in clinic or in
their place of residence as the patient specifies. If the one-
week assessment is not possible then the discharge assess-
ment is acceptable as the one-week outcome. Data will be
entered online or sent to the trial center via fax.
Three months, six months and twelve months
The main follow-up will be performed centrally at three
months, a standard procedure for most acute stroke tri-
als. Assessments will be based on a questionnaire sent to
the patient’s preferred follow-up address by the central
team, after checking with the GP that the patient is still
alive, unless the patient has specified a different prefer-
ence at the one-week assessment. Central follow-up will
ensure blinding of the assessors to the intervention. For
non-responders the address will be checked via the GP
and the local researcher and then resent. If there is no
response, patients will be contacted by phone to see if
they would prefer a personal follow-up or are happy to
reply to questions via the telephone. Missing or incon-
sistent data will be cross-checked with the medical
notes, with the GP, or by personal contact with the
patient. If patients are not contactable using these
methods, we will determine if they have died and, if so,
what the cause of death was by requesting information
from the Office of National Statistics or the NHS Stra-
tegic Tracing Service. The latter will also be contacted if
the patient is no longer resident at the address given and
the GP has not seen the patient recently and does not
know the patient’s new address and new GP.
The follow-up questionnaire will contain the modified
Rankin score (mRS) [47], Barthel Index of Activities of
Daily Living Score (ADL) [48], Nottingham Extended
Activities of Daily Living (NEADL) index [49], EQ-5DTM
[50-52], and questions regarding memory, sleep, speech
and discharge status.
Outcome measures
The primary outcome is measured using the mRS score
at three months [53]. Secondary outcomes are measured
at one week using: the number of patients with neuro-
logical improvement (≥4 point decrease in the NIHSS)
[54], the number of deaths, the highest oxygen satur-
ation during the first 72 hours, and the lowest oxygen
saturation during the first 72 hours. Further secondary
outcomes are measured at three months using: the mor-
tality rate, the percentage of patients living at home, the
Barthel ADL score, the EuroQol score and the Notting-
ham Extended Activities of Daily Living scale (NEADL).
Further explanatory analyses include: antibiotic and
sedative use during week one, the highest heart rate dur-
ing the intervention >100, the highest systolic blood
pressure during the intervention >200 mm Hg, the high-
est diastolic blood pressure during the intervention
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the percentage of patients describing their memory as
‘as good as before the stroke’, the percentage of patients
describing their sleep as ‘as good as before the stroke’,
the percentage of patients without significant speech
problems, and the change in outcomes over time (three
month assessments repeated at six and twelve months).
Those outcomes concerning memory, sleep and speech
have been highlighted as important on the public consult-
ation [55], but are not part of standard assessment scales
for stroke outcome.
All study measures will be performed by research staff
appropriately trained in the use of the assessment tools.
Data management and evaluation
Randomization
Patients will be randomized using minimized randomization
stratified by well validated prognostic factors (age, sex,
living alone, normal verbal component of the GCS, ability
to lift both arms and ability to walk) [56,57], routine oxy-
gen treatment during ambulance transfer, and baseline
oxygen saturation, via a web-based randomization system.
Randomization will not be stratified by the study center as
this may result in unacceptably high rates of allocation
prediction and selection bias [58]. However, retrospective
analysis by center will be performed to investigate any het-
erogeneity of treatment effect by center.
Data management
The local investigators, their research assistants, and
data monitors will have access to the patient records.
Personalized data (address, telephone number, email and
fax) will be kept in the trial office, as electronic copies
within each of the centers, and at the coordinating cen-
ter to allow patients to be contacted for the three-, six-
and twelve-month follow-up and to allow data checks
and validation.
For all other purposes patient identifiable data will be
converted to an alphanumeric code, using a specific
code number for each patient. The principal investiga-
tors, members of the trial steering group, the trial man-
agers, data managers, data monitors, the data analysts/
programmers, and the trial statisticians will have access
to the anonymized data.
Data will be stored on password protected office com-
puters and on Zip discs, flash drives or CD-ROMs. At
least three back-up copies will be made of all data. These
will be kept in locked cupboards in separate buildings.
Data will be transmitted via fax, email or the web from
each local center to the trial coordinator and data queries
will be transmitted via the same route from the trial co-
ordinator to local centers. Anonymized data may be made
available to other researchers for meta-analysis and publi-
cation in media such as the Cochrane Database.Statistical analysis
The analysis will be by intention to treat. The primary
outcome is the mRS score, which has an ordinal range
of 0 (best outcome) to 5 (worst outcome). This will be
measured at three months (or at the last rating). Deaths
will be allocated an arbitrary score of 6 [58]. A later pri-
mary outcome assessment at six months was considered,
but rejected because there is a risk of diluting treatment
effects by newly occurring health problems unrelated to
the trial intervention [59].
The trial tests two research hypotheses: 1. oxygen sup-
plementation results in better (lower) mRS scores at
three months than no oxygen supplementation; 2. Oxy-
gen administered at night results in better mRS scores
than oxygen given over a 24 hour period.
It cannot be assumed that any benefits from oxygen will
be dose dependent. Oxygen supplementation throughout
the 24-hour period may expose a significant number of
patients to oxygen concentrations higher than normal. Be-
ing attached to oxygen may also limit mobility and hinder
early mobilization. Oxygen given at night only will provide
supplementation at a time when oxygen saturation is low-
est in stroke patients, and will not interfere with rehabili-
tation. A prior hypothesis is that oxygen at night will have
all the potential advantages without the disadvantages as-
sociated with daytime oxygen use.
The mRS will be compared between two groups using
ordinal logistic regression [60]. Both an unadjusted and an
adjusted analysis will be performed. The latter will incorp-
orate the following covariates: age, sex, baseline NIHSS
score, and the ‘six simple variables’ (SSV) prognostic index
for independence at six months. The SSV score is based on
the following variables: age, living alone before the stroke,
independent pre-stroke, normal verbal response to ques-
tions, able to lift the affected arm against gravity, and able
to walk unaided [56,57]. Planned subgroup analyses for the
primary outcome are: baseline SSV prognostic index (<0.2,
0.2 to 0.35, 0.36 to 0.7, >0.7), NIHSS score at baseline
(<5, ≥5), baseline oxygen saturation (<95, ≥95), treatment
with oxygen prior to randomization (yes or no), time since
onset of stroke in hours (<4, 4 to 6, 7 to 12, 13 to 24, >24),
type of stroke (hemorrhage, infarction). Mortality will be
assessed using survival analysis, and other secondary out-
comes will be analyzed using appropriate statistical
methods. All tests will be two-tailed and 95% confidence
intervals will be calculated for all estimates of effect.
Study size
Many acute stroke studies have been underpowered be-
cause the expected treatment effect was unrealistically
large [61]. While thrombolysis within three hours of
acute stroke has been shown to lead to moderate clinical
benefits (0.5 points on the mRS) [58], neuroprotectant
treatments may well achieve lesser (for example, 0.2
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such a common condition and oxygen supplementation
is inexpensive and universally available, even relatively
small differences in outcome could have a major impact
on the burden of the disease. For example, treating five
patients with an average improvement of 0.2 mRS would
improve one patient by one mRS category (for example
from moderate disability to slight disability). However
though important, small differences do require very large
trials in order to show effectiveness.
The sample size calculation is based on an odds ratio of
0.83 for a more adverse outcome (higher mRS score) for
the oxygen and control groups, observed in the first 200 pa-
tients in the Stroke Oxygen Pilot Study (ISRCTN12362720)
[24,25] (C Roffe, P Jones, S Sills, personal communica-
tion). The sample size allows for a 5% drop-out rate for
such things as retrospective exclusions for a change of
diagnosis (numbers based on the Stroke Oxygen Pilot
study) plus a 5% rate of missing outcome data (this
overall 10% loss to follow-up gives a safe margin; target
would be less than 3%).
A sample size of 6,000 patients will therefore provide
95% power to detect the specified odds ratio between
oxygen (continuous and night only groups combined)
and no oxygen at p ≤ 0.05 (two-tailed), and 87% power at
p ≤ 0.05 (two-tailed) to detect the same effect between
continuous oxygen and oxygen at night only. Adjust-
ment for a maximum 10% loss to follow-up gives a tar-
get sample size of 6,669.
Increase of sample size in October 2012
A sample size of 8,000 patients will be used, as increasing
the recruitment target would give greater power to detect
an interaction between subgroups (defined by severity)
and the effect of oxygen versus control. The magnitude of
the increase in power can be estimated by considering the
increase in power to detect the pre-specified odds ratio of
0.83 in the subgroup of ‘moderate through to very severe’
patients (those with an NIHSS score greater than or equal
to 10, who are more likely to benefit from the treatment).
Using a revised loss to follow-up rate of 5%, power to de-
tect the specified odds ratio between oxygen and control
in this subgroup would rise from 43% to 50%. For the
whole sample, power to detect this effect between oxygen
treatment and no oxygen treatment will rise from 95% to
approximately 98% and that for the comparison of con-
tinuous oxygen and oxygen at night will rise from 87% to
approximately 94%.
Ethical requirements
Approval of the study by the research ethics committee
Multicenter ethical approval was granted for version 2 of
the protocol by the North Staffordshire Research Ethics
Committee on 25 June 2008 (COREC 06/Q2604/109).Good clinical practice
The study will be performed in accordance with the
principles stated in the Declaration of Helsinki [63].
Study procedures will be guided by the standards out-
lined in the MRC Guidelines for Good Clinical Practice
in Clinical Trials [64].
Patient information and consent
Consent will be obtained according to the requirements
of the Multicentre Research Ethics Committee and the
Local Research Ethics Committee before the start of
recruitment.
The patient, and where appropriate the next of kin,
will be given full and adequate oral and written informa-
tion about the nature and purpose of the study, possible
risks and benefits. A copy of the patient information
sheet and the signed consent/assent will be given to the
patient. Patients will be informed that they are free to
discontinue participation in the study at any time.
Fully informed consent will be sought from all compe-
tent subjects. In patients who are conscious, but not
fully competent to understand the information to make
a reasoned decision, we will provide a simple explan-
ation of the trial and seek the patient’s agreement, and
also seek assent from the next of kin or from an inde-
pendent physician. If an incompetent individual has
been included in the trial without giving fully informed
consent we will strive to obtain fully informed consent
as soon as the patient is able to do so. This will be docu-
mented on the one-week follow-up form.
The reason for including patients unable to give fully
informed consent is that roughly one third of stroke
patients will have problems with speech and with the
understanding of spoken and written material as a
consequence of their stroke. It is important to include
these patients in the study since they are just as likely to
benefit from the treatment as patients who are able to
communicate.
It is further important to include as wide a spectrum of
stroke patients as possible, in particular patients with se-
vere strokes. Patients with severe strokes may be more
likely to develop hypoxia, and may therefore be more
likely to benefit from oxygen treatment than patients with
mild strokes. However, patients with severe strokes are
more likely to be confused, drowsy or dysphasic, and thus
unable to give informed consent. Exclusion of subjects un-
able to give informed consent is thus likely to bias trial
outcome. Furthermore, since the group of patients who
are unable to consent has different clinical characteristics
from patients who can give consent, the results of the
study may not be applicable to patients with similar clin-
ical presentations to the excluded patients.
The information sheets to be given to patients, rela-
tives, or the independent clinician have been reviewed
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Monitoring of suspected unexpected serious adverse reactions
All suspected unexpected serious adverse reactions
(SUSARs) that are believed to be due to the trial treat-
ment will be reported as soon as possible within one
working day of the clinician becoming aware of the
event by phoning the study helpline or by emailing
christine.roffe@northstaffs.nhs.uk. A SUSAR report form
will be completed as fully as possible and sent, via
fax, to the Chief Investigator and the sponsor (North
Staffordshire Combined Healthcare Trust Research and
Development). On this form the patient will be identi-
fied by a unique identifying number consisting of the
trial identification number (ISRCTN) followed by the
number the patient was allocated at randomization.
The SUSAR form will be filed in the trial master file and
in the case record form. A SUSAR follow-up form will
be completed as soon as possible within five days of the
event and submitted via fax to the coordinating center
and sponsor. This will also be filed in the trial master file
and the case record form. Unless the event has resolved
or a decision has been taken that no further follow-up is
required, further follow-up forms will be completed,
faxed and filed as outlined above until the event has re-
solved. Relevant details of the SUSAR and its follow-up
will also be recorded in the patient’s medical notes. The
sponsor will inform the licensing authority, the compe-
tent authorities of any member state in which the trial is
being conducted, and the relevant Research Ethics Com-
mittee (West Midlands – Staffordshire Research Ethics
Committee, Barlow House, 3rd Floor, 4 Minshull Street,
Manchester, M1 3DZ, Fax 01785 254 640) of the SUSAR
as soon as possible, and no later than seven days after
first becoming aware of the event. The sponsor will pro-
vide details of follow-up reports and resolution. The
sponsor will also inform all the principal investigators of
the trial of the SUSAR. At the end of each year from the
start of the trial the sponsor will provide the licensing
authority (Medicines and Healthcare products Regula-
tory Authority, UK) with a list of all SUSARs relating to
the trial during that year and any other relevant new in-
formation relating to the investigational product which
may affect the conduct of this trial.
Data protection
Data will be stored and analyzed in accordance with na-
tional data legislation. Personalized data (address, tele-
phone number, email and fax) will be kept in the trial
office and as electronic copies within each of the centers
and at the coordinating center to allow patients to be
contacted for follow-up, and to allow data checks and
validation. For all other purposes patient identifiabledata will be converted to an alphanumeric code, using a
specific code number for each patient.
Trial administration
Sponsor
North Staffordshire Combined Healthcare NHS Trust,
Trust Headquarters, Bellringer Road, Trentham, ST4 8HH.
Person authorized by the sponsor to act on behalf of the
sponsor
R&D Director, North Staffordshire Combined Health-
care NHS Trust, Trust Headquarters, Bellringer Road,
Trentham, ST4 8HH. Tel: 01782 441651.
Chief investigator
Professor C Roffe, North Staffordshire Combined Health-
care NHS Trust, Holly Lodge, 62 Queens Road, Hartshill,
Stoke-on-Trent ST4 7LH. Tel 0300 123 0891 Fax 0300
123 0894, email: christine.roffe@northstaffs.nhs.uk.
Trial management committee
The trial management committee (TMC) is responsible
for the overall design and conduct of the study, analysis
of the data, reporting and dissemination of results. It will
act on advice of the trial steering committee, the data
safety and management committee, the advisory groups
and the international advisory committee.
Membership: Professor C Roffe (chair, stroke physician,
clinical lead of the West Midlands Local Stroke Research
Network); Professor P Crome (geriatrician, clinical trialist
and pharmacologist), Primary Care & Population Health,
University College London; Professor R Gray (expertise in
large clinical trials), University of Oxford; Professor J Sim
(statistician), Keele University; Professor P Jones (statisti-
cian), Keele University; Mr Peter and Mrs Linda Handy
(patient representatives), Strokes R Us, Stoke-on-Trent.
Trial steering committee
The trial steering committee (TSC) will oversee the
study. Professor M Dennis (stroke physician, clinical
trialist), University of Edinburgh will act as independent
chairman. Other members are: Professor L Kalra (stroke
physician, clinical trialist), King’s College, London; Pro-
fessor S Maslin-Prothero (nursing, policy and practice in
the NHS); J Daniels (clinical trialist), Birmingham Clinical
Trials Unit; Mrs P Bell (patient representative, dysphasia
support); Professor R Lindley (international advisor, stroke
physician, clinical trialist); and members of the TMC.
Data monitoring and safety committee
The remit of the Data Monitoring and Safety Committee
(DMSC) will be to ensure that patients are not exposed
to unnecessary risks, by performing interim safety ana-
lyses, and to maintain patient safety. If oxygen treatment
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to the primary endpoints, then this may become appar-
ent before the target recruitment has been reached. Al-
ternatively, new evidence might emerge from other
sources that oxygen is definitely effective, ineffective, or
adverse. To protect against this, during the period of
recruitment to the study, interim analyses of major end-
points will be supplied, in strict confidence, to an inde-
pendent Data Monitoring and Safety Committee along
with updates on results of other related studies, and any
other analyses that the DMSC may request. The DMSC
will advise the chair of the TSC if, in their view, the ran-
domized comparisons in the trial have provided both (a)
‘proof beyond reasonable doubt’ that for all, or for some,
types of patient one particular treatment is definitely in-
dicated or definitely contraindicated in terms of a net
difference in the major endpoints; and (b) evidence that
might reasonably be expected to influence the patient
management of many clinicians who are already aware
of the other main trial results. Appropriate criteria of
proof beyond reasonable doubt cannot be specified pre-
cisely, but a difference of at least three standard devia-
tions in an interim analysis of a major endpoint may be
needed to justify halting, or modifying, the study prema-
turely. If this criterion were to be adopted, the exact
number of interim analyses is of little importance, so no
fixed schedule is proposed. The TSC can then decide
whether to close or modify any part of the trial. Unless
this happens, however, the TMC, the TSC, the investiga-
tors and all of the central administrative staff (except the
statisticians who supply the confidential analyses) will
remain unaware of the interim results.
The DMSC is chaired by Professor S Jackson (pharma-
cology, prescribing, clinical trials), King’s College London.
Other members will be Professor T Robinson (stroke
physician, clinical lead of the Trent Stroke Local Research
Network), University of Leicester, and Dr M Lewis (statis-
tician), Keele University.Trial status
The Stroke Oxygen Study has completed recruitment
and is in follow-up.Abbreviations
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